Radiation pneumonitis after stereotactic radiation therapy for lung cancer

Table 1 Summary of reports on Grade 2 radiation pneumonitis after stereotactic body radiation therapy

First author	Ref.	Year	Gy	Pt No.	Median PTV, cc	Median follow-up in months	G2- RP	G3 RP	G4 RP	G5 RP	RP factor 1	RP factor 2
Onishi	[32]	2004	18-75Gy/1-25Fr	245	NA	24	6.50%	1.20%	1.20%	0%
McGarry	[31]	2005	24Gy/3Fr	47	NA	NA	8.40%	4.30%	2.10%	0%
Takahashi	[40]	2006	15-30Gy	32	NA	18	12.50%		0%	6%
Yamashita	[8]	2007	48Gy/4-6Fr	25	43.9	17	28.00%	4%	4%	12%	CI
Baumann	[16]	2008	45Gy/3Fr	60	NA	23	NA	21%	0%	0%
Ricardi	[27]	2009	45Gy/3Fr or 26Gy/1Fr	60	NA	30.9	14.30%	3.20%	0%	0%	MLD
Borst	[10]	2009	35-60Gy/4-8Fr	128	9.6	16.1	10.90%	0.80%	0%	0%	MLD
Stephans	[13]	2009	60Gy/3Fr or 50Gy/5Fr	86	39.9/30.4	15.3	2.30%	0%	0%	0%
Rusthoven	[2]	2009	48-60Gy/3Fr	7	NA	15.4	2.60%
Yamashita	[39]	2010	48Gy/4Fr	117	NA	14.7	NA	1.70%	1.70%	6.00%	KL-6 and SP-D	IP-shadow
Timmerman	[23]	2010	60Gy/3Fr or 54Gy/3Fr	55	NA	34.4	NA	12.70%	3.60%	0%
Nagata	[20]	2010	48Gy/4Fr	104	NA	46.8	NA	6.20%	0%	0%
Guckenberger	[9]	2010	26Gy/1Fr or 37.5Gy/3Fr	59	33	13	18.60%	0%	0%	0%	MLD	V2.5-50
Ong	[28]	2010	55Gy/5Fr or 60Gy/8Fr	18	137	12.8	27.80%	11.10%	0%	0%	V5
Grills	[35]	2010	48Gy/4Fr or 60Gy/5Fr	58	NA	30	11%	2%	0%	0%
Stauder	[30]	2011	32-60Gy/3-5Fr	74	42.9	15.8	12.50%	2.30%	0%	1.10%	Max dose
Matsuo	[53]	2012	48Gy/4Fr	74	32.5	31.4	20.30%	1.40%	0%	0%	V25	PTV volume
Barriger	[29]	2012	24-66Gy/3-5Fr	84	48.3	17	9.40%	2%	0.40%	0%	MLD (4Gy)	V20 (4%)
Baker	[37]	2013	Multiple	240	37.6	15.6	11%	1.10%	0%	0%	MLD (6Gy)	V20 (10%)

MLD: Mean lung dose; NA: Not available.